ATP2A2

Across TCGA pan-cancer cohorts, ATP2A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP2A2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP2A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP2A2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where ATP2A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.664	1.000	.009	18	view →
HNSC	DFS	Median	III,IV	0.791	0.505	.004	14	view →
LUAD	DFS	Quartile	All	0.365	0.774	.010	11	view →
LSCC	OS	Median	All	1.000	0.937	.010	11	view →
PDAC	DFS	Median	All	0.331	0.482	.015	5	view →
GBM	DFS	Tertile	All	0.778	0.612	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP2A2–CCRCC (OS)

Open the CCRCC breakdown →